Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Sell
20
ITRM Quote, Financials, Valuation and Earnings
Last price:
$0.33
Seasonality move
:
-20.24%
Day range:
$0.33 - $0.35
52-week range:
$0.26 - $1.86
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
32.25x
P/B ratio:
--
Volume:
411.9K
Avg. volume:
954.3K
1-year change:
-81.78%
Market cap:
$15.3M
Revenue:
--
EPS (TTM):
-$0.75
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ITRM
Iterum Therapeutics Plc
|
$505K | -$0.24 | -- | -49.47% | $5.50 |
|
AMRN
Amarin Corp. Plc
|
$50.6M | $0.07 | -18% | -100% | $12.00 |
|
GHRS
GH Research Plc
|
-- | -$0.27 | -- | -62.11% | $32.61 |
|
JAZZ
Jazz Pharmaceuticals Plc
|
$1.2B | $6.40 | 6.17% | 106.38% | $214.06 |
|
PRTA
Prothena Corp. Plc
|
$666.7K | -$0.46 | -68.6% | -57.29% | $20.33 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ITRM
Iterum Therapeutics Plc
|
$0.34 | $5.50 | $15.3M | -- | $0.00 | 0% | 32.25x |
|
AMRN
Amarin Corp. Plc
|
$15.88 | $12.00 | $330.2M | -- | $0.00 | 0% | 8.28x |
|
GHRS
GH Research Plc
|
$15.55 | $32.61 | $964.6M | -- | $0.00 | 0% | -- |
|
JAZZ
Jazz Pharmaceuticals Plc
|
$160.25 | $214.06 | $9.7B | 15.09x | $0.00 | 0% | 2.35x |
|
PRTA
Prothena Corp. Plc
|
$9.05 | $20.33 | $487.2M | -- | $0.00 | 0% | 41.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ITRM
Iterum Therapeutics Plc
|
128.01% | 1.048 | 112.75% | 1.78x |
|
AMRN
Amarin Corp. Plc
|
1.45% | 3.053 | 1.98% | 2.35x |
|
GHRS
GH Research Plc
|
0.2% | 1.978 | 0.07% | 27.72x |
|
JAZZ
Jazz Pharmaceuticals Plc
|
57.83% | 0.175 | 67.81% | 1.24x |
|
PRTA
Prothena Corp. Plc
|
2.99% | 1.301 | 1.73% | 6.43x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ITRM
Iterum Therapeutics Plc
|
$15K | -$7.7M | -98.23% | -- | -1982.31% | -$7.9M |
|
AMRN
Amarin Corp. Plc
|
$21.2M | -$1.7M | -17.51% | -17.79% | -3.42% | -$12.8M |
|
GHRS
GH Research Plc
|
-$89K | -$16.5M | -16.82% | -16.86% | -- | -$14.5M |
|
JAZZ
Jazz Pharmaceuticals Plc
|
$828.9M | $161.5M | -3.78% | -9.16% | 14.34% | $429.4M |
|
PRTA
Prothena Corp. Plc
|
$1.5M | -$39.8M | -65.85% | -67.47% | -1646.42% | -$43.2M |
Iterum Therapeutics Plc vs. Competitors
-
Which has Higher Returns ITRM or AMRN?
Amarin Corp. Plc has a net margin of -2302.31% compared to Iterum Therapeutics Plc's net margin of -15.58%. Iterum Therapeutics Plc's return on equity of -- beat Amarin Corp. Plc's return on equity of -17.79%.
Company Gross Margin Earnings Per Share Invested Capital ITRMIterum Therapeutics Plc3.85% -$0.20 $26.4M AMRNAmarin Corp. Plc42.97% -$0.37 $465.6M -
What do Analysts Say About ITRM or AMRN?
Iterum Therapeutics Plc has a consensus price target of $5.50, signalling upside risk potential of 1501.63%. On the other hand Amarin Corp. Plc has an analysts' consensus of $12.00 which suggests that it could fall by -26.83%. Given that Iterum Therapeutics Plc has higher upside potential than Amarin Corp. Plc, analysts believe Iterum Therapeutics Plc is more attractive than Amarin Corp. Plc.
Company Buy Ratings Hold Ratings Sell Ratings ITRMIterum Therapeutics Plc1 0 0 AMRNAmarin Corp. Plc0 1 1 -
Is ITRM or AMRN More Risky?
Iterum Therapeutics Plc has a beta of 2.867, which suggesting that the stock is 186.66% more volatile than S&P 500. In comparison Amarin Corp. Plc has a beta of 0.722, suggesting its less volatile than the S&P 500 by 27.8%.
-
Which is a Better Dividend Stock ITRM or AMRN?
Iterum Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amarin Corp. Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iterum Therapeutics Plc pays -- of its earnings as a dividend. Amarin Corp. Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ITRM or AMRN?
Iterum Therapeutics Plc quarterly revenues are $390K, which are smaller than Amarin Corp. Plc quarterly revenues of $49.4M. Iterum Therapeutics Plc's net income of -$9M is lower than Amarin Corp. Plc's net income of -$7.7M. Notably, Iterum Therapeutics Plc's price-to-earnings ratio is -- while Amarin Corp. Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iterum Therapeutics Plc is 32.25x versus 8.28x for Amarin Corp. Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ITRMIterum Therapeutics Plc32.25x -- $390K -$9M AMRNAmarin Corp. Plc8.28x -- $49.4M -$7.7M
-
Which has Higher Returns ITRM or GHRS?
GH Research Plc has a net margin of -2302.31% compared to Iterum Therapeutics Plc's net margin of --. Iterum Therapeutics Plc's return on equity of -- beat GH Research Plc's return on equity of -16.86%.
Company Gross Margin Earnings Per Share Invested Capital ITRMIterum Therapeutics Plc3.85% -$0.20 $26.4M GHRSGH Research Plc-- -$0.23 $292M -
What do Analysts Say About ITRM or GHRS?
Iterum Therapeutics Plc has a consensus price target of $5.50, signalling upside risk potential of 1501.63%. On the other hand GH Research Plc has an analysts' consensus of $32.61 which suggests that it could grow by 109.7%. Given that Iterum Therapeutics Plc has higher upside potential than GH Research Plc, analysts believe Iterum Therapeutics Plc is more attractive than GH Research Plc.
Company Buy Ratings Hold Ratings Sell Ratings ITRMIterum Therapeutics Plc1 0 0 GHRSGH Research Plc6 0 0 -
Is ITRM or GHRS More Risky?
Iterum Therapeutics Plc has a beta of 2.867, which suggesting that the stock is 186.66% more volatile than S&P 500. In comparison GH Research Plc has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ITRM or GHRS?
Iterum Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GH Research Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iterum Therapeutics Plc pays -- of its earnings as a dividend. GH Research Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ITRM or GHRS?
Iterum Therapeutics Plc quarterly revenues are $390K, which are larger than GH Research Plc quarterly revenues of --. Iterum Therapeutics Plc's net income of -$9M is higher than GH Research Plc's net income of -$14M. Notably, Iterum Therapeutics Plc's price-to-earnings ratio is -- while GH Research Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iterum Therapeutics Plc is 32.25x versus -- for GH Research Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ITRMIterum Therapeutics Plc32.25x -- $390K -$9M GHRSGH Research Plc-- -- -- -$14M
-
Which has Higher Returns ITRM or JAZZ?
Jazz Pharmaceuticals Plc has a net margin of -2302.31% compared to Iterum Therapeutics Plc's net margin of 22.33%. Iterum Therapeutics Plc's return on equity of -- beat Jazz Pharmaceuticals Plc's return on equity of -9.16%.
Company Gross Margin Earnings Per Share Invested Capital ITRMIterum Therapeutics Plc3.85% -$0.20 $26.4M JAZZJazz Pharmaceuticals Plc73.6% $4.08 $9.4B -
What do Analysts Say About ITRM or JAZZ?
Iterum Therapeutics Plc has a consensus price target of $5.50, signalling upside risk potential of 1501.63%. On the other hand Jazz Pharmaceuticals Plc has an analysts' consensus of $214.06 which suggests that it could grow by 33.58%. Given that Iterum Therapeutics Plc has higher upside potential than Jazz Pharmaceuticals Plc, analysts believe Iterum Therapeutics Plc is more attractive than Jazz Pharmaceuticals Plc.
Company Buy Ratings Hold Ratings Sell Ratings ITRMIterum Therapeutics Plc1 0 0 JAZZJazz Pharmaceuticals Plc10 2 0 -
Is ITRM or JAZZ More Risky?
Iterum Therapeutics Plc has a beta of 2.867, which suggesting that the stock is 186.66% more volatile than S&P 500. In comparison Jazz Pharmaceuticals Plc has a beta of 0.272, suggesting its less volatile than the S&P 500 by 72.796%.
-
Which is a Better Dividend Stock ITRM or JAZZ?
Iterum Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Jazz Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iterum Therapeutics Plc pays -- of its earnings as a dividend. Jazz Pharmaceuticals Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ITRM or JAZZ?
Iterum Therapeutics Plc quarterly revenues are $390K, which are smaller than Jazz Pharmaceuticals Plc quarterly revenues of $1.1B. Iterum Therapeutics Plc's net income of -$9M is lower than Jazz Pharmaceuticals Plc's net income of $251.4M. Notably, Iterum Therapeutics Plc's price-to-earnings ratio is -- while Jazz Pharmaceuticals Plc's PE ratio is 15.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iterum Therapeutics Plc is 32.25x versus 2.35x for Jazz Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ITRMIterum Therapeutics Plc32.25x -- $390K -$9M JAZZJazz Pharmaceuticals Plc2.35x 15.09x $1.1B $251.4M
-
Which has Higher Returns ITRM or PRTA?
Prothena Corp. Plc has a net margin of -2302.31% compared to Iterum Therapeutics Plc's net margin of -1513.09%. Iterum Therapeutics Plc's return on equity of -- beat Prothena Corp. Plc's return on equity of -67.47%.
Company Gross Margin Earnings Per Share Invested Capital ITRMIterum Therapeutics Plc3.85% -$0.20 $26.4M PRTAProthena Corp. Plc60.95% -$0.68 $304.1M -
What do Analysts Say About ITRM or PRTA?
Iterum Therapeutics Plc has a consensus price target of $5.50, signalling upside risk potential of 1501.63%. On the other hand Prothena Corp. Plc has an analysts' consensus of $20.33 which suggests that it could grow by 124.68%. Given that Iterum Therapeutics Plc has higher upside potential than Prothena Corp. Plc, analysts believe Iterum Therapeutics Plc is more attractive than Prothena Corp. Plc.
Company Buy Ratings Hold Ratings Sell Ratings ITRMIterum Therapeutics Plc1 0 0 PRTAProthena Corp. Plc2 2 0 -
Is ITRM or PRTA More Risky?
Iterum Therapeutics Plc has a beta of 2.867, which suggesting that the stock is 186.66% more volatile than S&P 500. In comparison Prothena Corp. Plc has a beta of -0.093, suggesting its less volatile than the S&P 500 by 109.25%.
-
Which is a Better Dividend Stock ITRM or PRTA?
Iterum Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Prothena Corp. Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Iterum Therapeutics Plc pays -- of its earnings as a dividend. Prothena Corp. Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ITRM or PRTA?
Iterum Therapeutics Plc quarterly revenues are $390K, which are smaller than Prothena Corp. Plc quarterly revenues of $2.4M. Iterum Therapeutics Plc's net income of -$9M is higher than Prothena Corp. Plc's net income of -$36.5M. Notably, Iterum Therapeutics Plc's price-to-earnings ratio is -- while Prothena Corp. Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Iterum Therapeutics Plc is 32.25x versus 41.33x for Prothena Corp. Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ITRMIterum Therapeutics Plc32.25x -- $390K -$9M PRTAProthena Corp. Plc41.33x -- $2.4M -$36.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
65
RGC alert for Jan 10
Regencell Bioscience Holdings Ltd. [RGC] is up 10.55% over the past day.
Sell
50
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
